Status:
COMPLETED
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizoaffective Disorder
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to see if differences exist in outcome in patients with schizophrenia or schizoaffective disorder who were switched from other antipsychotics to ziprasidone.
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia or schizoaffective disorder
- Outpatients for at least 3 months on treatment with sulpiride, olanzapine, quetiapine, or risperidone and at least a partial beneficial response to typical antipsychotic treatment including for the current episode
- Partial improvement in symptoms that justified a switch to ziprasidone
Exclusion
- Diagnosis of major depression or occurrence of moderate depressive symptoms
- Resistance to conventional antipsychotic drugs
- Treatment with other drugs such as antiseizure medications, antipsychotics, antidepressants, or mood stabilizing agents that might interfere with the assessement of the efficacy of ziprasidone
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2004
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00649064
Start Date
December 1 2003
End Date
September 1 2004
Last Update
February 21 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Changhua, Taiwan
2
Pfizer Investigational Site
Tainan, Taiwan
3
Pfizer Investigational Site
Taipei, Taiwan